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What is already known about this subject
￿ Nonclinical studies have shown that exenatide is primarily
cleared by the renal system.
￿ It was not known to what degree the clinical
pharmacokinetics and tolerability would be affected by
increasing renal impairment (RI).
What this study adds
￿ Patients with mild to moderate RI adequately tolerate current
therapeutic doses of exenatide.
￿ However, exenatide is not recommended in patients with
severe RI or end-stage renal disease.
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Aims
To evaluate the pharmacokinetics (PK), safety and tolerability of a single exenatide
dose in patients with renal impairment (RI).
Methods
Exenatide (5 or 10 mg) was injected subcutaneously in 31 subjects (one with Type 2
diabetes) stratified by renal function [Cockcroft–Gault creatinine clearance (CrCL),
number of subjects]: normal (>80 ml min
-1, n = 8), mild RI (51–80 ml min
-1, n = 8),
moderate RI (31–50 ml min
-1, n = 7) or end-stage renal disease (ESRD) requiring
haemodialysis (n = 8). PK data were combined with four previous single-dose studies
in patients with Type 2 diabetes to explore the relationship of exenatide clearance
(CLp/F) and CrCL.
Results
Mean half-life for healthy, mild RI, moderate RI and ESRD groups were 1.5, 2.1, 3.2
and 6.0 h, respectively. After combining data from multiple studies, least squares
geometric means for CLp/F in subjects with normal renal function, mild RI, moderate
RI and ESRD were 8.14, 5.19, 7.11 and 1.3 l h
-1, respectively. Exenatide was generally
well tolerated in the mild and moderate RI groups, but not in subjects with ESRD due
to nausea and vomiting. Simulations of exenatide plasma concentrations also suggest
patients with ESRD should have a propensity for poor tolerability at the lowest
available therapeutic dosage (5 mg q.d.).
Conclusions
Since tolerability and PK changes were considered clinically acceptable in patients with
mild to moderate RI, it would be appropriate to administer exenatide to these patients
without dosage adjustment. However, poor tolerability and significant changes in PK
make the currently available therapeutic doses (5 and 10 mg) unsuitable in severe RI
or ESRD.
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Exenatide (exendin-4) is a 39-amino acid peptide
approved by the US Food and DrugAdministration as an
adjunctive treatment of Type 2 diabetes in patients
unable to achieve adequate control using metformin
and/or a sulphonylurea [1]. Exenatide, injected subcuta-
neously, at doses of 5 and 10 mg bid signiﬁcantly lowers
HbA1c and reduces body weight in patients with Type 2
diabetes, as shown by three 30-week placebo-controlled
trials [2–4]. It shares several glucoregulatory actions
with the endogenous incretin hormone, glucagon-like
peptide-1 (GLP-1) and has been shown in vitro to be an
agonist of the human islet GLP-1 receptor [5]. Exenatide
thus belongs to a new class of antidiabetic agents known
as incretin mimetics. GLP-1 is released in response to
meal-derived glucose and leads to glucose-dependent
enhancement of insulin secretion [6] and suppression of
inappropriately elevated glucagon secretion [7]. GLP-1
also slows the rate of gastric emptying [8].
Exenatide reaches peak plasma concentrations in
approximately 2 h, has a terminal half-life of approxi-
mately 2.5 h in human subjects with normal renal func-
tion [19] and is predominantly eliminated by renal
mechanisms. In anaesthetized pigs, extraction from
kidney, liver, lungs, intestine and leg tissue detected
exenatide only in the kidney, and by an amount equiva-
lent to that accounted for by glomerular ﬁltration [10].
Also, in nephrectomized rats, clearance was reduced
fourfold compared with control rats [11], indicating a
major role of the kidneys in exenatide elimination.After
renal ﬁltration, exenatide is enzymatically degraded in
the kidney tubules with negligible amounts of intact
exenatide being detected in the urine of rats [12].
Renal dysfunction is widely prevalent in patients
with diabetes. In the UKPDS 64 study, approximately
25% of patients with Type 2 diabetes had micro-
albuminuria and 5% had macroalbuminuria by 10 years
following diagnosis of diabetes [13]. Diabetic nephr-
opathy represents the most common cause of end-stage
renal failure, accounting for about 40% of all new cases
of end-stage renal disease (ESRD) in the USA [14].
Studies have shown that glycaemic control is important
to prevent development of diabetic nephropathy and
microvascular complications [15, 16]. As renal dys-
function develops, therapeutic options for patients with
Type 2 diabetes become more complicated. Impaired
renal function can reduce the clearance of drugs that are
extensively cleared by the kidneys, thereby increasing
the incidence of exposure-dependent side-effects.
Hence, it is important to explore the effects of renal
impairment (RI) on novel antidiabetic medications such
as exenatide.
This study evaluated the pharmacokinetics, safety and
tolerability of a single subcutaneous administration of
exenatide in patients with mild or moderate RI or ESRD
compared with subjects with healthy renal function.
Pharmacokinetic simulations based on those results
were used to predict the steady-state proﬁles for the
moderate-RI and ESRD groups. In addition, a combined
analysis with four previous pharmacokinetic studies in
patients with Type 2 diabetes was performed to quantify
further the relationship between exenatide clearance and
creatinine clearance. These complementary analyses
were the basis for exenatide dosage recommendations
for patients with various stages of RI.
Methods
Subjects and study groups
Male and female subjects, between 25 and 80 years of
age and with a body mass index (BMI) of between 19
and 40 kg m
-2, were eligible to enter this open-label
study. Thirty-one eligible subjects were stratiﬁed into
four parallel study groups based on their renal function
(Cockcroft–Gault creatinine clearance, CrCL) at screen-
ing. The groups were classiﬁed as having normal renal
function (control group CrCL > 80 ml min
-1, n = 8),
mild RI (CrCL 51–80 ml min
-1, n = 8), moderate RI
(CrCL 31–50 ml min
-1, n = 7) at screening or ESRD (on
haemodialysis for at least 1 month before screening,
n = 8). Subjects in the healthy control group were, as
practically possible, age and gender matched to subjects
in the RI groups. Subjects with impaired renal function
were allowed to continue their concomitant medication
for the treatment of renal disease. Control subjects were
not permitted concomitant medications, apart from hor-
monal contraception. RI groups could include subjects
with Type 2 diabetes controlled by diet alone and/or by
sulphonylureas.
The study protocol and informed-consent document
were approved by the ethical review boards at the City
Hospitals ofAntwerp, General St Jean Hospital of Brus-
sels and theAcademic Hospital of the Free University of
Brussels. The study was conducted at three sites in
Belgium according to good clinical practices, all local
laws and regulations and the Declaration of Helsinki.
Informed consent was obtained from all study subjects
before participation.
Drug administration, dosing and sample collection
Subjects were admitted to the study centre either on the
day of dosing (day 1) or the previous evening, and
remained resident in the unit until day 2, approximately
24 h postdose. A single subcutaneous injection of 5 or
10 mg exenatide was administered into the abdomen
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on day 1. Subjects were provided lunch, afternoon snack
and evening meal at speciﬁed times following the dose.
To minimize the potential safety and tolerability risk
posed by increased drug accumulation with RI, dosing
was to commence with the mild RI group. Each subject
in this group received a single subcutaneous dose of
10 mg exenatide and safety and tolerability data from at
least three subjects were evaluated prior to the dosing of
subjects with moderate RI. Subjects with moderate RI or
ESRD could be given a lower dose if deemed clinically
necessary. Similarly, dosing of subjects with ESRD was
based on evaluation of pharmacokinetic, safety and tol-
erability data from at least three subjects with moderate
renal dysfunction. Dosing in subjects with ESRD
occurred during the longest weekly interval between
dialysis sessions to allow for adequate pharmacokinetic
sampling prior to the next dialysis. The effects of dialy-
sis in patients with ESRD were to be evaluated in this
study by measuring plasma exenatide concentrations
before (48 h postdose) and after a dialysis cycle.
To accommodate longer half-lives in the renal impair-
ment groups, sampling durations were prolonged rela-
tive to the healthy group. Serial blood samples (3 ml) for
the measurement of exenatide plasma concentrations
were taken postdose up to 12 h (normal renal function),
18 h (mild and moderate RI) and 48 h (ESRD). Plasma
samples were analysed for exenatide concentration
using a validated immunoenzymetric assay over the
range 10–500 pg ml
-1 as previously described [17]. The
overall relative standard deviation, which is an expres-
sion of the precision, ranged between 3.7% and 16.2%.
The overall relative error, which is an expression of the
accuracy, ranged between -11.0% and +17.3% for all
concentrations.
Safety assessment
Supine vital signs (blood pressure and heart rate) and
12-lead ECG were assessed for all subjects at scheduled
intervals from predose to 24 h postdose. In addition,
standing vital signs were assessed for the control group.
Blood samples for the measurement of plasma glucose
concentrations were also taken during the study at
scheduled intervals and if hypoglycaemia was sus-
pected. Adverse events were recorded as they occurred
during the study. Physical examinations were conducted
for each subject at 24 h and at 4–15 days after dosing.
Pharmacokinetic analyses
Exenatide plasma concentrations were evaluated by
standard noncompartmental methods to determine key
pharmacokinetic parameters. The maximum concentra-
tion (Cmax) and the time of maximum concentration (tmax)
were identiﬁed from the observed data. The area under
the plasma exenatide concentration–time curve
(AUC0–•) was calculated using the log linear trapezoidal
rule. The dose-weight normalized Cmax andAUC0–• were
log transformed and evaluated by analysis of variance
(anova). One subject with moderate RI was excluded as
an outlier from statistical analyses for having unusually
low exenatide concentrations compared with the rest of
the group. Based on predeﬁned criteria, plasma concen-
trations for this subject were deemed to be outliers
because they were less than three times the SD of the
mean of the rest of the subjects. The differences in least
square (LS) geometric means between each of the RI
groups and the healthy group were transformed back to
the original scale to yield the ratio of the geometric
means and the corresponding 90% conﬁdence interval
(CI) for each comparison. WinNonLin Professional 3.1
(Pharsight, Cary, NC, USA) and SAS 8.2 for Windows
(SAS Inc., Cary, NC, USA) software were used for the
pharmacokinetic and statistical analyses, respectively.
Combined analysis of renal study with previous studies
Exenatide pharmacokinetic parameters derived from this
study were combined with those from four previous
single-dose studies [18–20] and stratiﬁed by renal func-
tion. These previous studies were conducted in patients
with Type 2 diabetes. In contrast, the renal study
included only one subject with Type 2 diabetes in the
mild RI group. Nonetheless, this combination is justiﬁed
from a pharmacokinetic perspective because exenatide
clearance in patients with Type 2 diabetes has been
shown to be similar to that of healthy subjects [9] and
the same bioanalytical assay was used in all studies
from which the data were combined. Of the previous
trials, Studies ‘A’ and ‘B’ were single-blind, placebo-
controlled studies: the former was dose-rising over 0.1–
0.4 mgk g
-1, the latter conducted at 0.1 mgk g
-1. Study
‘C’ was a double-blind, placebo-controlled, single-dose
rising study over 0.05–0.2 mgk g
-1. Study ‘D’was a ran-
domized, open-label, single-dose crossover study using
10 mg exenatide.As these previous studies had crossover
designs, they included subjects who were dosed on more
than one occasion and multiple pharmacokinetic (PK)
parameter estimates could therefore be derived for each
subject. A linear mixed-effects model was used for sta-
tistical analysis where subject was a random effect and
RI group was a ﬁxed effect to take into account the
correlation among multiple observations from the same
subject. The ratios of the LS geometric means and the
corresponding 90% CI were calculated for AUC0–• and
Cmax estimates from each of the RI groups compared
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analysis dataset. Furthermore, the relationship between
exenatide clearance and creatinine clearance was evalu-
ated by ﬁtting a linear mixed-effects model. Clearance
for the severe RI group was estimated by interpolation
from the linear regression line over a creatinine clear-
ance range of 10–30 ml min
-1.
Nonparametric simulation of single dose pharmacokinetic
data
Steady-state concentration–time proﬁles were projected
by nonparametric simulations of single-dose plasma
concentration–time proﬁles from this renal study using
WinNonLin Professional 3.1 (Pharsight). Simulations
were conducted on the mean, lowest and highest single-
dose concentration–time proﬁles for RI groups that
showed a statistically signiﬁcant increase in exposure
compared with the control group. Projected steady-state
proﬁles were compared with a range of plasma exenatide
concentrations that are known to be efﬁcacious and tol-
erated (50–350 pg ml
-1).
Results
Study groups
Table 1 provides demographic characteristics including
mean creatinine clearance, gender, age, weight and BMI
for the four study groups. The groups were comparable
with respect to gender and BMI, but age varied more
because of the higher age in the moderately impaired
group compared with the control group. All subjects
were nondiabetic, except for one subject in the mild RI
group who had Type 2 diabetes controlled by diet and
exercise. Subjects with normal renal function and mild
RI received a 10-mg exenatide dose. Following review of
the PK, safety and tolerability in the mild RI group, it
was decided to reduce the dose to 5 mg in the moderate
group. Two subjects with moderate RI were adminis-
tered 10 mg of exenatide inadvertently, but did not expe-
rience any adverse events. Similarly, based on evaluation
of data in the moderate group, subjects with ESRD were
administered 5 mg of exenatide.
Safety and tolerability
Table 2 displays the frequency of adverse events
reported by subjects during the study.The most common
treatment-emergent adverse events were vomiting,
nausea and headache. Most episodes occurred within
approximately 2.5 h of dosing.The nature and frequency
of adverse events were comparable between the control
(10 mg), mild RI (10 mg) and ESRD groups (5 mg). No
adverse events were observed for the group with mod-
erate RI (5 and 10 mg exenatide). Antiemetic concomi-
tant medications (mostly metoclopramide) were
administered to seven subjects with ESRD, one with
mild RI and one in the healthy group because of more
severe or longer-duration nausea or vomiting. No sub-
jects discontinued the study due to adverse events.
Three adverse events for two subjects were rated
severe. One control subject experienced severe nausea
that began 40 min postdose, lasted approximately 3 h
and was treated with oral administration of metoclopra-
mide. This subject had a peak plasma exenatide concen-
tration of 1295 pg ml
-1, 1 h after administration of
Table 1
Study group descriptions
Study groups†
Mean
creatinine
clearance
(range),
ml min-1 n
Exenatide
dose, mg
Gender
distribution,
male : female
Age,
mean  SD,
years
Body
weight
SD, kg
BMI,
mean  SD,
kg m-2
Healthy (control) 111 (83–156) 8 10 3 : 5 46  5.5 73.3  10.9 25.7  4.08
Mild RI 68 (60–78) 8 10 5 : 3 56  9.9 76.9  13.3 25.5  2.77
Moderate RI 45 (34–50) 7 5 or 10‡ 5 : 2 64  9.6* 76.1  12.6 27.2  3.02
ESRD N/A 8 5 3 : 5 52  18.3 64.1  13.5 23.7  3.29
*P < 0.05, compared with normal renal function group. BMI, Body mass index; RI, renal impairment; ESRD, end-stage renal
disease. †Inclusion criteria for study groups based on Cockcroft–Gault creatinine-clearance (CrCL): normal renal function: CrCL
>80 ml min-1; Mild RI: CrCL 51–80 ml min-1; Moderate RI: CrCL 31–50 ml min-1; ESRD: haemodialysis for at least 1 month at
screening. ‡Five patients received 5 mg and two patients received 10 mg exenatide.
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of vomiting. The ﬁrst episode began approximately 1 h
postdose, lasted 30 min and was treated with intravenous
administration of metoclopramide. The second episode
began approximately 4 h postdose, lasted 10 min and
was treated with intravenous administration of aliza-
pride. This subject reached a peak exenatide plasma
concentration of 494 pg ml
-1, 2 h after administration of
5 mg. Both subjects had exenatide plasma concentrations
similar to others within their treatment group.
Transient increases in supine systolic and diastolic
blood pressure were observed 1–3 h after exenatide
dosing. Mean peak increases from predose baselines for
the treatment groups ranged from 11 to 18 mmHg for
systolic and 6 to 12 mmHg for diastolic blood pressures.
In addition, transient increases in supine heart rate were
apparent 3–8 h postdose, with the mean peak increases
from baselines ranging from 10 to 17 beats min
-1 among
the groups.
Two subjects each experienced one adverse event of
mild tachycardia. One (healthy subject) began approxi-
mately 3 h postdose and lasted 21 h, although it was not
apparent in the 12-lead ECG assessed at 3, 6 and 24 h
postdose. The other (ESRD subject) occurred approxi-
mately 1 h postdose, lasted 7 h and was considered clini-
cally signiﬁcant by ECG assessment at 3 h postdose.
Exenatide exposures (Cmax and AUC0–•) for these two
subjects were below their respective group means.
Transient reductions in plasma glucose concentrations
were observed for most subjects 0.5–2 h following
exenatide dosing, consistent with exenatide’s glucose-
lowering actions. However, no subjects had symptoms
of hypoglycaemia.
Exenatide pharmacokinetics
Mean plasma exenatide concentration–time proﬁles and
PK parameters are shown by study group in Figure 1 and
Table 3, respectively. Mean exenatide clearance (CLp/F)
was substantially reduced in subjects with ESRD
(0.9 l h
-1) compared with the control group (3.4 l h
-1).
Consistent with the change in clearance, mean half-life
increased as renal function decreased from normal renal
function (1.5 h) to mild (2.1 h) and moderate RI (3.2 h).
The longest half-life occurred with ESRD (6 h), which
was four times that of subjects with normal renal func-
tion. The effect of dialysis could not be evaluated in
patients with ESRD because exenatide concentrations
were below the quantiﬁcation limit 48 h postdose, prior
to the subsequent dialysis cycle.
The statistical comparison of exenatide clearance and
dose–weight normalized exenatide exposure between
each renal impairment group and the normal renal group
(Table 4) showed mild to moderate RI was not signiﬁ-
cantly different with respect to clearance orAUC0–•,b u t
yielded a mean Cmax approximately 32–35% lower than
the healthy control group. For the ESRD group, the
clearance was approximately one-quarter of the healthy
control group (P < 0.001) and dose–weight normalized
AUC0–• and Cmax were 3.37 (P < 0.001) and 1.38
Table 2
Treatment-emergent adverse events reported by subjects
MedDRA
preferred term
Number of adverse events [number of subjects with adverse event]
Healthy subjects
(10 mg exenatide)
(n = 8)
Mild RI
(10 mg exenatide)
(n = 8)
Moderate RI
(5 mg exenatide)*
(n = 7)
ESRD
(5 mg exenatide)
(n = 8)
Vomiting NOS 9 [6] 6 [3] 0 10 [7]
Nausea 8 [8] 1 [1] 0 8 [7]
Headache† 7 [5] 2 [2] 0 6 [5]
Dizziness 1 [1] 3 [2] 0 0
Malaise 0 0 0 2 [2]
Tachycardia 1 [1]‡ 0 0 1 [1]§
Other¶ 2 [1] 5 [2] 0 1 [1]
Total 28 [8] 17 [5] 0 28 [7]
*Two subjects in this group received 10 mg exenatide. †Five headache events were probably not related to exenatide. ‡Medical
Dictionary for Regulatory Activities (MedDRA) term: Tachycardia NOS (NOS = not otherwise specified). §MedDRA term: Sinus
tachycardia. ¶Dyspepsia, cold sweat and increased sweating (not related to hypoglycaemia), asthenia (twice), dry throat,
abdominal pain upper, dyspnoea. Each reported by one subject.
Exenatide pharmacokinetics in renal-impaired patients
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control group.
Combined analysis of renal study with previous studies
Four of the eight subjects in the control group exhibited
exenatide plasma concentrations substantially higher
(Cmax 960–1996 pg ml
-1) than expected due to exenatide
clearance being substantially lower (CLp/F 2.13–
3.16 l h
-1) than expected. The mean peak exenatide
plasma concentration and apparent clearance typically
observed following a 10-mg subcutaneous dose in sub-
jects with normal renal function is approximately
200 pg ml
-1 and 9 l h
-1, respectively [1]. Therefore, to
provide a more robust control sample, results from this
renal study were combined with previously available
data from four single-dose crossover studies. The
previous studies included 67 subjects with Type 2 dia-
betes (50 male, 17 female); mean  SD for the key
demographics were: age 52.3  8.77 years, BMI
33  4.71 kg m
-2, weight 97.1  18 kg. The majority of
subjects in the previous studies had normal renal
function [CrCL 140  47.5 ml min
-1 (n = 63)]; how-
ever, four subjects exhibited mild RI (CrCL
71.5  5.62 ml min
-1).
LS geometric mean clearances in the normal renal
function, mild RI, moderate RI and ESRD groups in the
combined-studies analysis were 8.14, 7.11, 5.19 and
1 . 3lh
-1, respectively (Table 5). These clearance esti-
mates differ from those in Table 3 because of the lower
than usual clearance estimates for some subjects in the
renalstudycontrolgroup.Resultsofthecombinedanaly-
sis showed that exenatide clearance was not signiﬁcantly
different between the normal renal function and mild
renalimpairmentgroups(P = 0.26),butwassigniﬁcantly
reduced by 36% in the moderate renal impairment group
(P = 0.008) and 84% in the ESRD group (P < 0.001)
compared with the normal control group (Table 5).
Exenatide exposure (Cmax and AUC) from the
combined-analysis dataset was compared between sub-
jects with RI and those with normal renal function
Figure 1
Mean (SD) plasma exenatide
concentration–time profiles for subjects
with (A) normal renal function and mild renal
impairment (RI) following a 10-mg dose;
(B) moderate RI and end-stage renal disease
(ESRD) following a 5-mg dose. Two subjects
in the moderate RI group who received 10 mg
exenatide are not shown. ( , Healthy
(10 mg); , Mild (10 mg); , Moderate
(5 mg); ,E S R D( 5mg))
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Table 3
Exenatide pharmacokinetic parameters by renal group in the single study
Parameter (units)
Geometric mean (CV%)
Healthy Mild RI Moderate RI * ESRD
n 885 1 8
Dose (mg) 10 10 5 10 5
Cmax (pg ml
-1) 821 (61.0) 470 (24.6) 202 (19.9) 353 601 (69.4)
AUC0–• ( p ghm l
-1) 2930 (31.4) 2080 (17.4) 1150 (15.2) 2090 5380 (42.2)
CLp/F (l h
-1) 3.4 (31.4) 4.8 (17.4) 4.4 (14.2) 0.9 (42.2)
Vz/F (l) 7.1 (40.2) 14.7 (21.9) 20.2 (45.1) 8 (43.9)
t1/2 (h)† 1.5 (0.9–2.0) 2.1 (1.6–3.4) 3.2 (1.8–7.0) 6 (4.3–7.6)
Tmax (h)† 2.0 (1.0–3.0) 2.0 (0.5–3.0) 2.50 (1.0–3.0) 2.0 (1.0–4.0)
*One subject in the 10-mg group was excluded as an outlier from all statistical evaluations. †t1/2 and Tmax represented as mean
(range) and median (range), respectively.
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anAUC 1.63 times that of the control group (P = 0.003)
and patients with ESRD had an increase in AUC 6.24
times that of the control group (P < 0.001). To illustrate
further the signiﬁcance of these comparisons, simula-
tions of steady-state exenatide plasma proﬁles using dif-
ferent regimens were conducted and are described in the
section below.
Table 4
Comparison of exenatide clearance and dose–weight normalized AUC0–• and Cmax between each renal impairment group
(mild, moderate and ESRD) and the healthy control group
Renal
function group n
LS
geometric
mean
LS geometric mean ratio
renal group/healthy
(90% CI) P-value
AUC0–•
( p ghm l -1)/(mgk g -1)
Healthy 8 19 917 –
Mild RI 8 16 036 0.81 (0.66, 0.98) 0.066
Moderate RI* 6 19 258 0.97 (0.77, 1.21) 0.801
ESRD 8 67 102 3.37 (2.80, 4.06) <0.001
Cmax (pg ml
-1)/(mgk g
-1) Healthy 8 5 392 –
Mild RI 8 3 650 0.68 (0.49, 0.93) 0.047
Moderate RI* 6 3 507 0.65 (0.45, 0.94) 0.060
ESRD 8 7 434 1.38 (1.01, 1.88) 0.088
CLp/F (l h-1) Healthy 8 3.64 – –
Mild RI 8 4.72 1.30 (1.02, 1.66) 0.08
Moderate RI
a 6 4.07 1.12 (0.84, 1.49) 0.52
ESRD 8 0.94 0.26 (0.20, 0.33) 0.001
*One subject receiving 10 mg was excluded as an outlier due to atypically low concentrations. ESRD, End-stage renal disease; RI,
renal impairment.
Table 5
Comparison of exenatide clearance and dose–weight-normalized AUC0–• and Cmax between the renal impairment groups
(mild, moderate and ESRD) and the control group using data from multiple trials*
Pharmacokinetic
parameter
Renal
function group n
LS
geometric
mean
LS geometric mean ratio
renal group/normal
(90% CI) P-value
AUC0–•
( p ghm l
-1)/(mgk g
-1)
Normal 71 10 913 – –
Mild RI 12 12 842 1.18 (0.97, 1.42) 0.156
Moderate RI 6 17 751 1.63 (1.25, 2.12) 0.003
ESRD 8 68 054 6.24 (4.94, 7.87) <0.001
Cmax (pg ml
-1)/(mgk g
-1) Normal 71 2 312 – –
Mild RI 12 2 708 1.17 (0.92, 1.49) 0.284
Moderate RI 6 3 098 1.34 (0.95, 1.89) 0.160
ESRD 8 7 595 3.28 (2.43, 4.44) <0.001
CLp/F (l h
-1) Normal 71 8.14 – –
Mild RI 12 7.11 0.87 (0.69, 1.11) 0.258
Moderate RI* 6 5.19 0.64 (0.46, 0.89) 0.008
ESRD 8 1.3 0.16 (0.12, 0.22) <0.001
* Clearance estimates for subjects with normal renal function were obtained by combining the control group of the renal study
and four historical studies in subjects with Type 2 diabetes. ESRD, End-stage renal disease; RI, renal impairment.
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creatinine clearance was evaluated by mixed-effects
regression analysis (Figure 2). The majority of observed
data were contained within the 95% conﬁdence bands of
the regression line. Based on the linear regression
between exenatide clearance and creatinine clearance,
predicted mean exenatide clearance for patients with
severe RI (CrCL 10–30 ml min
-1) ranged from 1.82 to
3.03 l h
-1.
Simulations based on the single-dose data from
renal study
Figure 3 shows the simulated exenatide plasma
concentration–time proﬁles for several treatment regi-
mens in patients with moderate RI or ESRD at steady
state. These proﬁles overlay a reference therapeutic
range of 50–350 pg ml
-1 (shaded area), which is typical
among patients with normal renal function administered
5 and 10 mg [19, 20]. Exenatide concentrations
>350 pg ml
-1 resulted in a notable increased incidence of
nausea [19]. The mean simulated exenatide concentra-
tion proﬁle in patients with moderate RI following a
5-mg bid regimen remained below 350 pg ml
-1, whereas
much of the simulated concentration proﬁle following
10 mg bid exceeded this range for 2–4 h postdose. For
patients with ESRD, most of the mean simulated
exenatide concentrations following a 5-mg q.d. regimen
were >350 pg ml
-1 for much of the dosing interval;
however, following a 2.5-mg q.d. regimen the mean
simulated concentrations remained below 350 pg ml
-1.
Discussion
This study explored the inﬂuence of varying degrees of
RI on exenatide safety, tolerability and PK to assess
potential dosage adjustment that may be needed for
patients at different stages of renal disease. Therapeutic
exenatide dosage regimens (5–10 mg bid) were assessed
in patients at different stages of renal disease in keeping
with recommendations from the European Medicines
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Relationship between exenatide clearance and creatinine clearance
(r = 0.63, P < 0.001) showing the regression (solid line) and 95%
confidence interval (broken lines). (, Previous Studies Combined
(Healthy); , Renal Study (Healthy); , Renal Study (Mild RI); ,
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Figure 3
Simulated steady-state profiles based on the
nonparametric superposition of single-dose
data for exenatide at several regimens in
patients with moderate renal impairment (RI)
or end-stage renal disease (ESRD). Solid and
broken lines represent nonparametric
simulation of lowest, mean and highest
concentration profile of each group. The
shaded area (50–350 pg ml
-1) is the typical
therapeutically efficacious and tolerable range
for exenatide in patients with normal renal
function
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CLp/F in the healthy group was substantially lower than
that observed previously in subjects with a normal renal
function [1]. Therefore, previous data from four single-
dose studies in 67 patients with Type 2 diabetes were
combined with the data of the renal study.The combined
analysis showed that, whilst exenatide clearance
decreased 13% in the mild-RI group compared with
subjects with a normal renal function, tolerability of
exenatide (10 mg) was acceptable and this reduction in
clearance was not considered clinically relevant; there-
fore, no dosage adjustment is recommended for patients
with mild RI. In patients with moderate RI, exenatide
clearance decreased by 36%. Patients with moderate RI
tolerated 5 and 10 mg exenatide, although PK simula-
tions for 10 mg bid suggested many patients with
moderate RI could brieﬂy experience exenatide
concentrations >350 mg ml
-1 and therefore might expe-
rience periods of reduced tolerance following 10 mg
exenatide. Patients with ESRD had signiﬁcantly reduced
clearance (84% decrease) and did not adequately toler-
ate 5 mg exenatide; therefore, current therapeutic
dosages of exenatide are not recommended for this
group.
The moderate RI group had a statistically signiﬁcant
increase in exenatide exposure, with a dose–weight nor-
malized AUC of 1.63 times the control group; however,
exenatide (5 and 10 mg) was well tolerated in the mod-
erate RI group. PK simulations for this subpopulation
suggest steady-state concentrations following a 5-mg
dose given bid are likely to be retained in a therapeuti-
cally effective and tolerable range (50–350 pg ml
-1).
However, simulations also show a 10-mg dose given bid
to patients with moderate RI will be likely to result in
concentrations that exceed this range, although for rela-
tively short duration and by a relatively small magni-
tude. Dosing with exenatide is recommended to
commence at 5 mg bid with escalation to 10 mg bid after
at least 1 month based on the individual’s tolerability
and efﬁcacy proﬁle [1]. Although simulations have
shown relatively minor excursions above tolerable con-
centrations in patients with moderate RI, and the two
patients in this study with moderate RI who were admin-
istered 10 mg exenatide tolerated it well, therapeutic
escalation from 5 to 10 mg bid by patients with moderate
RI should be done conservatively.
The ESRD group had a statistically signiﬁcant
increase in exenatide exposure with a dose-normalized
AUC of 6.24 times the healthy group. A substantial
reduction in exenatide clearance was expected given the
results of the preclinical studies that indicated a major
contribution of the kidneys to the elimination of
exenatide. The simulated steady-state concentration pro-
ﬁles after 5 mg q.d. in patients with ESRD were substan-
tially higher than 350 pg ml
-1 threshold for a major
portion of the dosing interval, suggesting prolonged
periods of poor tolerability with ESRD. Given the poor
tolerability observed in this study with 5 mg exenatide,
which is currently the lowest therapeutic dosing option,
it is recommended that exenatide not be administered to
patients with ESRD. The lower 2.5-mg q.d. regimen
simulated for ESRD resulted in a mean exenatide con-
centration proﬁle within the therapeutically efﬁcacious
and tolerable range (<350 pg ml
-1); however, this has not
been clinically tested.
This study did not include a group with severe RI
(CrCL  30 ml min
-1 and not on haemodialysis).
However, interpolation from a linear ﬁt of exenatide
clearance vs. creatinine clearance for patients with
severe RI showed a relatively low mean exenatide clear-
ance of 1.82–3.03 l h
-1 for this subgroup. Given this low
clearance and the poor tolerability of a single 5-mg dose
in patients with ESRD, currently available therapeutic
regimens of exenatide are also not recommended for
patients with severe RI.
Antidiabetic therapy in patients with ESRD and
severe RI could be an unmet medical need due to limited
therapy choices, and alternate dosing regimens of
exenatide could be explored. Given our simulation
results showing the predicted mean exenatide plasma
concentration proﬁle <350 pg ml
-1 with a 2.5-mg q.d.
regimen, it would be reasonable to explore further a
reduced dosage in patients with ESRD or severe RI. The
design of any such future clinical studies to target efﬁ-
cacious and tolerable exposures at lower doses in
patients with severe RI or ESRD will be guided by
additional PK simulations.
In this renal study, mean apparent clearance in the
mild RI group was higher than in the healthy control
group. This was an artefact of the relatively low mean
clearance estimate obtained in the control group due to
four patients with substantially higher exposures than
previously observed in patients with normal renal func-
tion. While plausible explanations such as bioanalytical
or dosing error were investigated, a deﬁnitive reason for
the observation was not established. Therefore, PK
results from this study were combined with those from
four previous single-dose PK studies to provide an
evaluation of the relationship of individual clearance
estimates over a wide continuum of creatinine clearance.
The historical database was composed of patients with
Type 2 diabetes compared with the renal study, where all
except one patient did not have diabetes. As previous
analyses have established that exenatide clearance is
Exenatide pharmacokinetics in renal-impaired patients
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volunteers [9] and the bioanalytical methodology was
the same in every study, combining these datasets was
justiﬁed. Notably, the historical database contributed not
only data from subjects with normal renal function, but
also 11 observations with mild renal impairment. As a
result, numerical differences exist in exposure estimates
shown in Tables 4 and 5 for subjects with normal renal
function and mild renal impairment and could be
explained by the addition of these data. In order to avoid
bias, statistical analyses from both the renal study alone
and the combined analysis are presented, and are con-
sidered complementary.
In this study, a single 5- or 10-mg subcutaneous dose
of exenatide appeared generally well tolerated in all
evaluated stages of renal function except the ESRD
group. Overall, the incidences of nausea and vomiting in
each group were generally related to exenatide plasma
concentrations, which can be mitigated by dosage man-
agement. In long-term exenatide clinical trials, the inci-
dence of nausea with 5 mg bid was less than with 10 mg
bid [2–4].The same studies also found that the incidence
of nausea decreased over time with either dosage due to
increased tolerance.
Transient increases from baseline in blood pressure
and heart rate were observed with exenatide treatment in
this study; however, the lack of placebo control and the
potential confounding effects of renal disease and con-
comitant medications limit interpretation of these
results. Although acute increases were demonstrated
here after a single dose, no differences between placebo
and exenatide treatments were observed for blood pres-
sure or heart rate (measured at clinic visits), or cardio-
vascular adverse events in the 30-week exenatide
clinical trials [2–4].
In conclusion, no dosage adjustment of exenatide is
required for patients with mild to moderate RI because
the recommended starting dosage of 5 mg was well tol-
erated and any subsequent increase in dosage would be
based on the patient’s individual tolerance and glycae-
mic response. However, as mean exenatide clearance
was signiﬁcantly reduced and a single 5-mg dose of
exenatide was not well tolerated in subjects with ESRD,
this dosage may not be suitable for use in patients with
ESRD or severe RI (creatinine clearance <30 ml min
-1).
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